NEA 17 Files SC 13D for MBX Biosciences
Ticker: MBX · Form: SC 13D · Filed: Sep 23, 2024 · CIK: 1776111
Sentiment: neutral
Topics: filing-update, venture-capital, ownership-change
TL;DR
NEA 17 just updated their MBX Biosciences stake filing. Watch this space.
AI Summary
New Enterprise Associates 17, L.P. (NEA 17) and its group members, including individuals like Ali Behbahani and Scott D. Sandell, have filed a Schedule 13D on September 23, 2024, related to their holdings in MBX Biosciences, Inc. The filing indicates a change in their reporting status or ownership, though specific share counts and dollar amounts are not detailed in this excerpt.
Why It Matters
This filing signals a significant update from a major venture capital firm regarding their stake in MBX Biosciences, potentially impacting investor perception and future strategic moves for the company.
Risk Assessment
Risk Level: medium — Schedule 13D filings often precede significant corporate actions or changes in control, introducing uncertainty.
Key Players & Entities
- New Enterprise Associates 17, L.P. (company) — Filing entity
- MBX Biosciences, Inc. (company) — Subject company
- Ali Behbahani (person) — Group member
- Scott D. Sandell (person) — Group member
- NEA 17 GP, LLC (company) — Group member
- NEA PARTNERS 17, L.P. (company) — Group member
FAQ
What specific changes in beneficial ownership are detailed in this SC 13D filing for MBX Biosciences, Inc.?
The provided excerpt does not specify the exact number of shares or percentage of ownership change, only that a Schedule 13D was filed by New Enterprise Associates 17, L.P. and its group members on September 23, 2024.
Who are the named group members associated with New Enterprise Associates 17, L.P. in this filing?
The group members listed include Ali Behbahani, Anthony A. Florence, Jr., Carmen Chang, Edward T. Mathers, Forest Baskett, Mohamad H. Makhzoumi, NEA 17 GP, LLC, NEA Partners 17, L.P., Paul Walker, Rick Yang, and Scott D. Sandell.
What is the business address and phone number for MBX Biosciences, Inc.?
The business address for MBX Biosciences, Inc. is 12406 Horesham Street, Carmel, IN 46032, and the business phone number is 317-989-3100.
What is the Central Index Key (CIK) for MBX Biosciences, Inc. and New Enterprise Associates 17, L.P.?
The CIK for MBX Biosciences, Inc. is 0001776111, and the CIK for New Enterprise Associates 17, L.P. is 0001768564.
Under which act and file number is this SC 13D filing submitted?
This SC 13D filing is submitted under the Securities Exchange Act of 1934, with SEC File Number 005-94623.
Filing Stats: 4,555 words · 18 min read · ~15 pages · Grade level 8.2 · Accepted 2024-09-23 18:05:24
Key Financial Figures
- $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
- $16.00 — squo;s Common Stock at the IPO price of $16.00 per share. Prior to the Closing, NEA
- $30,815,700.35 — uo;) for an aggregate purchase price of $30,815,700.35. Immediately prior to the Closing, the
Filing Documents
- nea17-mbx_18882.htm (SC 13D) — 456KB
- 0001072613-24-000721.txt ( ) — 458KB
Purpose
Item 4. Purpose of Transaction . NEA 17 acquired the NEA 17 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer’s business or corporate structure; (g) Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above. Item 5. Interest in Securities of the Issuer . (a) NEA 17 is the record owner of the NEA 17 Shares. As the general partner of NEA 17, NEA Partners 17 may be deemed to own beneficially the N